

PCT

WELTORGANISATION FÜR GEISTIGES EIGENTUM Internationales Büro INTERNATIONALE ANMELDUNG VERÖFFENTLICHT NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES PATENTWESENS (PCT)

(51) Internationale Patentklassifikation 6: C07D 487/04, 471/04, A61K 31/435, 31/495, 31/415 // (C07D 487/04, 241:00, 231:00, 307:00) (C07D 471/04, 221:00, 231:00, 307:00) (C07D 471/04, 231:00, 307:00) (C07D 471/04, 231:00, 221:00, 239:00) (C07D 471/04, 231:00,

(11) Internationale Veröffentlichungsnummer: WO 98/23619

(43) Internationales Veröffentlichungsdatum: 4. Juni 1998 (04.06.98)

(21) Internationales Aktenzeichen:

221:00, 263:00)

196 49 460.5

PCT/EP97/06366

(22) Internationales Anmeldedatum:

14. November 1997 (14.11.97)

A1

(30) Prioritätsdaten:

26. November 1996 (26.11.96) DE

(71) Anmelder (für alle Bestimmungsstaaten ausser US): BAYER AKTIENGESELLSCHAFT [DE/DE]; D-51368 Leverkusen (DE).

(72) Erfinder; und

(75) Erfinder/Anmelder (nur für US): STRAUB, Alexander [DE/DE]; Moospfad 30, D-42113 Wuppertal (DE). ROBYR, Chantal [CH/DE]; Bismarckstrasse 23, D-45470 Mülheim (DE). JAETSCH, Thomas [DE/DE]; Eintra-chstrasse 105, D-50668 Köln (DE). FEURER, Achim [DE/DE]; Schlinghofenerstrasse 36, D-51519 Odenthal (DE), KAST, Raimund [DE/DE]; Badische Strasse 7, D-42389 Wuppertal (DE). STASCH, Johannes-Peter [DE/DE]; Alfred-Nobel-Strasse 109, D-42651 Solingen Veröffentlicht

(DE), PERZBORN, Elisabeth [DE/DE]; Am Tescher Busch 13, D-42327 Wuppertal (DE), HÜTTER, Joachim [DE/DE]; Teschensudberger Strasse 13, D-42349 Wuppertal (DE). DEMBOWSKY, Klaus [DE/DE]; Bismarckstrasse 85, D-42115 Wuppertal (DE).

(74) Gemeinsamer Vertreter: BAYER AKTIENGE-SELLSCHAFT: D-51368 Leverkusen (DE).

(81) Bestimmungsstaaten: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO Patent (GH, KE, LS, MW, SD, SZ, UG, ZW), eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), europäisches Patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Mit internationalem Recherchenbericht,

Vor Ablauf der für Änderungen der Ansprüche zugelassenen Frist. Veröffentlichung wird wiederholt falls Änderungen eintreffen.

(54) Title: NOVEL SUBSTITUTED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CARDIOCIRCULATORY DISEASES

(54) Bezeichnung: NEUE SUBSTITUIERTE PYRAZOLDERIVATE ZUR BEHANDLUNG VON HERZKREISLAUFERKRANKUN-GEN

(57) Abstract

The present invention relates to novel substituted pyrazole derivatives, a method for the production and the use thereof as a medicament, specially as a medicament to treat cardiocirculatory diseases.

(57) Zusammenfassung

Die vorliegende Erfindung betrifft neue substituierte Pyrazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel, insbesondere als Arzneimittel zur Behandlung von Herzkreislauferkrankungen.

Le 17 32 120 = AU partul WO: 729642

(12) PATENT (19) AUSTRALIAN PATENT OFFICE (11) Application No. AU 199854823 B2

(10) Patent No. 729642

(54) Title
Novel substituted pyrazole derivatives for the treatment of cardiocirculatory

Novel substituted pyrazole derivatives for the treatment of cardiocirculator diseases

(51)⁷ International Patent Classification(s) C07D 487/04 A61K 031/495 A61K 031/415 C07D 471/04 A61K 031/435

(21) Application No: 199854823 (22) Application Date: 1997.11.14

(87) WIPO No: WO98/23619

(30) Priority Data

(31) Number (32) Date (33) Country 19649460 1996.11.26 DE

(43) Publication Date: 1998.06.22
(43) Publication Journal Date: 1998.08.13
(44) Accepted Journal Date: 2001.02.08

(71) Applicant(s)
Bayer Aktiengesellschaft

(72) Inventor(s) Alexander Straub; Chantal Robyr; Thomas Jaetsch; Achim Feurer; Ralmund Kast; Johannes-Peter Stasch; Elisabeth Perzborn; Joachim Hutter; Klaus Dembowsky

(74) Agent/Attorney
DAVIES COLLISON CAVE.GPO Box 3876,SYDNEY NSW 2001



AU9854823

(51) Internationale Patentklassifikation 6:

C07D 487/04, 471/04, A61K 31/435, 31/495, 31/415 // (C07D 487/04, 241:00, 231:00, 307:00) (C07D 471/04, 221:00, 231:00, 307:00) (C07D 471/04, 231:00, 221:00, 239:00) (C07D 471/04, 231:00,

(11) Internationale Veröffentlichungsnummer: WO 98/23619

A1 (43) Internationales Veröffentlichungsdatum:

4. Juni 1998 (04.06.98)

221:00, 263:00) (21) Internationales Aktenzeichen:

PCT/EP97/06366

(22) Internationales Anmeldedatum:

14. November 1997 (14.11.97)

(30) Prioritätsdaten: 196 49 460.5

26. November 1996 (26.11.96) DE

(71) Apmelder (für alle Bestimmungsstaaten ausser US): BAYER AKTIENGESELLSCHAFT [DE/DE]; D-51368 Leverkusen (DE)

(72) Erfinder: und

(75) Erfinder/Anmelder (nur für US): STRAUB, Alexander (DE/DE): Moospfad 30, D-42113 Wuppertal (DE), ROBYR, Chantal [CH/DE]; Bismarckstrasse 23, D-45470 Mülheim (DE). JAETSCH, Thomas [DE/DE]; Eintrachstrasse 105, D-50668 Köln (DE), FEURER, Achim [DE/DE]; Schlinghofenerstrasse 36, D-51519 Odenthal (DE), KAST, Raimund [DE/DE]; Badische Strasse 7, D-42389 Wuppertal (DE), STASCH, Johannes-Peter [DE/DE]; Alfred-Nobel-Strasse 109, D-42651 Solingen (DE). PERZBORN, Elisabeth [DE/DE]: Am Tescher Busch 13, D-42327 Wuppertal (DE), HÜTTER, Joachim [DE/DE]; Teschensudberger Strasse 13, D-42349 Wuppertal (DE). DEMBOWSKY, Klaus [DE/DE]: Bismarckstrasse 85, D-42115 Wuppertal (DE),

(74) Gemeinsamer Vertreter: BAYER AKTIENGE-SELLSCHAFT; D-51368 Leverkusen (DE).

(81) Bestimmungsstaaten: AL, AM, AT, AU, AZ, BA, BB, BG, BR. BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO. NZ. PL. PT, RO, RU, SD. SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO Patent (GH, KE, LS, MW, SD, SZ, UG, ZW), eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), europäisches Patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, Cl, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Veröffentlicht

Mil internationalem Recherchenbericht.

Vor Ablauf der für Änderungen der Ansprüche zugelassenen Frist. Veröffentlichung wird wiederholt falls Anderungen eintreffen.

(54) Title: NOVEL SUBSTITUTED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CARDIOCIRCULATORY DISEASES

(54) Bezeichnung: NEUE SUBSTITUIERTE PYRAZOLDERIVATE ZUR BEHANDLUNG VON HERZKREISLAUFERKRANKUN-

(57) Abstract

The present invention relates to novel substituted pyrazole derivatives, a method for the production and the use thereof as a medicament, specially as a medicament to treat cardiocirculatory diseases.

(57) Zusammenfassung

Die vorliegende Erfindung betrifft neue substituierte Pyrazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel, insbesondere als Arzneimittel zur Behandlung von Herzkreislauferkrankungen.

Patent claims

Substituted pyrazole derivatives of the general formula (I)

$$\begin{array}{c|c}
R^{1} & R^{2} \\
N & R^{3} \\
\hline
CH_{1} & A
\end{array}$$
(I)

in which

5

10

R¹ represents a saturated or aromatic 5- or 6-membered heterocycle having up to 3 heteroatoms from the group consisting of S, N and/or O, which can be bonded via a nitrogen atom and which is optionally substituted up to 3 times identically or differently by amino, azido, formyl, mercaptyl, carboxyl, hydroxyl, straight-chain or branched acyl, alkoxy, alkylthio or alkoxycarbonyl each having up to 6 carbon atoms, nitro, cyano, halogen, phenyl or straight-chain or branched alkyl having up to 6 carbon atoms, which for its part can be substituted by hydroxyl, amino, azido, carboxyl, straight-chain or branched acyl, alkoxy, alkoxycarbonyl or acylamino each having up to 5 carbon atoms or by a radical of the formula -OR⁴.

15 in which

R⁴ denotes straight-chain or branched acyl having up to 5 carbon atoms or a group of the formula -SiR⁵R⁶R⁷,

in which

R⁵, R⁶ and R⁷ are identical or different and denote aryl having 6 to 10 carbon atoms or alkyl having up to 6 carbon atoms,



and/or is substituted by a radical of the formula

-S(O)_c-NR⁹R¹⁰,

in which

- a, b and b' are identical or different and denote a number 0, 1, 2 or 3.
 - R⁸ denotes hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms,
 - c denotes a number 1 or 2 and
- R⁹ and R¹⁰ are identical or different and denote hydrogen or straight-chain or branched alkyl having up to 10 carbon atoms, which can optionally be substituted by cycloalkyl having 3 to 8 carbon atoms or by aryl having 6 to 10 carbon atoms, which for its part can be substituted by halogen, or

denote aryl having 6 to 10 carbon atoms, which is optionally substituted by halogen, or denote cycloalkyl having 3 to 7 carbon atoms, or

R⁹ and R¹⁰, together with the nitrogen atom, form a 5- to 7membered saturated heterocycle which can optionally contain a further oxygen atom or a radical -NR¹¹, in which

5

10

15



R¹¹ denotes hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms or a radical of the formula

phenyl, where the ring systems are optionally substituted by halogen.

R² and R³, including the double bond, form a 6-membered saturated or aromatic heterocycle having up to 3 heteroatoms from the group consisting of N, S and/or O, which is optionally substituted up to 3 times identically or differently by formyl, carboxyl, hydroxyl, mercaptyl, straight-chain or branched acyl, alkylthio or alkoxycarbonyl each having up to 6 carbon atoms, nitro, cyano, halogen or straight-chain or branched alkyl or alkoxy each having up to 6 carbon atoms, which for its part can be substituted by hydroxyl, amino, carboxyl, straight-chain or branched acyl, alkoxy or alkoxycarbonyl each having up to 5 carbon atoms.

and/or the heterocycle is optionally substituted by a group of the formula -NR¹³R¹³ or -S(O)..NR⁹R¹⁰, in which

R¹² and R¹³ are identical or different and denote hydrogen or straightchain or branched alkyl having up to 6 carbon atoms, or

R12 denotes hydrogen and

R13 denotes formyl

c', R⁹ and R¹⁰ have the meaning of c, R⁹ and R¹⁰ indicated above and are identical to or different from these

5

10

15



and/or the heterocycle is optionally substituted by phenyl which for its part can be substituted up to 2 times identically or differently by halogen or by straight-chain or branched alkyl or alkoxy each having up to 6 carbon atoms

and/or the heterocycle is optionally substituted by a group of the formula -N=CH-NR¹⁴R¹⁵, in which

R¹⁴ and R¹⁵ are identical or different and denote hydrogen, phenyl or straight-chain or branched alkyl having up to 6 carbon atoms,

represents a 5- or 6-membered aromatic or saturated heterocycle having up to 3 heteroatoms from the group consisting of S, N and/or O or phenyl, each of which is optionally substituted up to 3 times identically or differently by amino, mercaptyl, hydroxyl, formyl, carboxyl, straightchain or branched acyl, alkylthio, alkyloxyacyl, alkoxy or alkoxycarbonyl each having up to 6 carbon atoms, nitro, cyano, trifluoromethyl, azido, halogen, phenyl or straight-chain or branched alkyl having up to 6 carbon atoms, which for its part can be substituted by hydroxyl, carboxyl, straight-chain or branched acyl, alkoxy or alkoxycarbonyl each having up to 5 carbon atoms.

and/or is substituted by a group of the formula -(CO)_d-NR¹⁶R¹⁷,

20 in which

d denotes a number 0 or 1.

R¹⁶ and R¹⁷ are identical or different and denote hydrogen, phenyl, benzyl or straight-chain or branched alkyl or acyl each having up to 5 carbon atoms,



5

10

and their isomeric forms and salts.

- 2. Compounds of the general formula (I) according to Claim 1, in which
 - R¹ represents pyrimidinyl, pyridazinyl, pyridyl, pyrazinyl, tetrahydropyranyl, tetrahydrofuranyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, thiazolyl, 1,2,3-triazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, isoxazolyl, isothiazolyl, pyranyl or morpholinyl, each of which is optionally substituted up to 3 times identically or differently by amino, formyl, mercaptyl, carboxyl, hydroxyl, straight-chain or branched acyl, alkoxy, alkylthio or alkoxycarbonyl each having up to 5 carbon atoms, nitro, cyano, azido, fluorine, chlorine, bromine, phenyl or straight-chain or branched alkyl having up to 5 carbon atoms, which for its part can be substituted by hydroxyl, amino, azido, carboxyl, straight-chain or branched acyl, alkoxy, alkoxycarbonyl or acylamino each having up to 4 carbon atoms or by a radical of the formula -OR*.
- 15 in which

5

10

R⁴ denotes straight-chain or branched acyl having up to 4 carbon atoms.

and/or by a radical of the formula

-S(O),-NR9R10,

in which



- a, b and b' are identical or different and denote a number 0, 1, 2 or 3,
- R⁸ denotes hydrogen or straight-chain or branched alkyl having up to 3 carbon atoms,
- c denotes a number 1 or 2 and

R9 and R10 are identical or different and denote hydrogen or straightchain or branched alkyl having up to 9 carbon atoms, which can optionally be substituted by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or naphthyl or phenyl, which for their part can be substituted by fluorine or chlorine, or denote phenyl or naphthyl, each of which is optionally substituted by fluorine or chlorine, or denote cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, or

 R^9 and R^{10} , together with the nitrogen atom, form a morpholine ring or a radical of the formula

R11 denotes hydrogen, methyl or a radical of the formula

R² and R³, including the double bond, form a pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl ring, each of which is optionally substituted up to 3 times identically or differently by formyl, carboxyl, hydroxyl, mercaptyl,



20

5

10

straight-chain or branched acyl, alkylthio or alkoxycarbonyl each having up to 5 carbon atoms, nitro, cyano, azido, fluorine, chlorine, bromine or straight-chain or branched alkyl or alkoxy each having up to 5 carbon atoms, which for its part can be substituted by hydroxyl, amino, carboxyl, straight-chain or branched acyl, alkoxy or alkoxycarbonyl each having up to 4 carbon atoms.

and/or the abovementioned heterocyclic rings are optionally substituted by a group of the formula -NR $^{12}R^{13}$ or -S(O)_cNR $^{9}R^{10}$, in which

 R^{12} and R^{13} are identical or different and denote hydrogen or straightchain or branched alkyl having up to 4 carbon atoms, or

R12 denotes hydrogen and

R13 denotes formyl

c', R^{ϕ} and R^{10} have the meaning of c, R^{ϕ} and R^{10} indicated above and are identical to or different from these

and/or the abovementioned heterocyclic rings are optionally substituted by phenyl, which for its part can be substituted by fluorine, chlorine, bromine or by straight-chain or branched alkyl or alkoxy each having up to 4 carbon atoms

and/or the abovementioned heterocyclic rings are optionally substituted by a group of the formula $NR^{14}R^{15}$, in which

R 14 and R 15 denote hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms.

10





A represents thienyl, tetrahydropyranyl, tetrahydrofuranyl, phenyl, morpholinyl, pyrimidyl, pyrrazinyl, pyridazinyl or pyridyl, each of which is optionally substituted up to 2 times identically or differently by hydroxyl, formyl, carboxyl, straight-chain or branched acyl, alkylthio, alkoxyacyl, alkoxy or alkoxycarbonyl each having up to 4 carbon atoms, fluorine, chlorine, bromine, nitro, cyano, trifluoromethyl or straight-chain or branched alkyl having up to 4 carbon atoms, which for its part can be substituted by hydroxyl, carboxyl, straight-chain or branched acyl, alkoxy or alkoxycarbonyl each having up to 4 carbon atoms,

and/or by a group of the formula -(CO)d-NR16R17,

in which

d denotes a number 0 or 1.

R¹⁶ and R¹⁷ are identical or different and denote hydrogen, phenyl, benzyl or straight-chain or branched alkyl or acyl each having up to 4 carbon atoms,

and their isomeric forms and salts.

- 3. Compounds of the general formula (I) according to Claim 1, in which
 - R¹ represents imidazolyl, furyl, pyridyl, pyrrolyl, pyrazinyl, pyrimidyl, isoxazolyl, oxazolyl or thiazolyl, each of which is optionally substituted up to 3 times identically or differently by formyl, fluorine, chlorine, amino, mercaptyl, cyano, straight-chain or branched acyl, alkylthio, alkoxy or alkoxycarbonyl each having up to 4 carbon atoms or straight-chain or branched alkyl having up to 4 carbon atoms, which for its part can be substituted by hydroxyl, carboxyl, amino, azido, straight-chain or branched acyl, alkoxy, alkoxycarbonyl or acylamino each having up to

225

5

10

15

3 carbon atoms.

and/or by a radical of the formula

$$- \langle \begin{matrix} CH_2 \\ \\ CCH_2 - (CH_2)_\bullet \end{matrix}, \quad - \langle \begin{matrix} CCH_2 \\ \\ CCH_2 - CH_3 \end{matrix}, \quad \begin{matrix} CCH_2 \\ \\ CCH_2 \end{matrix} \rangle_{b} - CH_3 \quad , \quad \begin{matrix} II \\ N \\ CR^8 \end{matrix}$$
 or

-S(O)c-NR9R10

in which

- a, b and b' are identical or different and denote a number 0, 1 or 2,
- R8 denotes hydrogen or methyl,
- c denotes a number 1 or 2 and

R⁹ and R¹⁰ are identical or different and denote hydrogen or straightchain or branched alkyl having up to 9 carbon atoms, which can optionally be substituted by phenyl or naphthyl, or denote phenyl or naphthyl, each of which is optionally substituted by fluorine or chlorine, or denote cyclopropyl or cycloheptyl, or

 R^9 and R^{10} , together with the nitrogen atom, form a morpholine ring or a radical of the formula

R¹¹ denotes hydrogen, methyl or a radical of the formula

10



ring systems are optionally substituted by chlorine,

R² and R³, including the double bond, form a pyridyl, pyrazinyl, pyrimidinyl or pyridazinyl ring, each of which is optionally substituted up to 3 times identically or differently by formyl, mercaptyl, carboxyl, hydroxyl, straight-chain or branched acyl, alkoxy, alkylthio or alkoxycarbonyl each having up to 4 carbon atoms, nitro, cyano, fluorine, chlorine or straight-chain or branched alkyl or alkoxy each having up to 3 carbon atoms, which for its part can be substituted by hydroxyl, amino, carboxyl, straight-chain or branched acyl, alkoxy or alkoxycarbonyl each having up to 3 carbon atoms.

and/or the heterocyclic rings are optionally substituted by amino, N,N-dimethylamino or by a radical of the formula -NH-CHO or -N=CH-N(CH₃)₂ and/or by phenyl, which for its part can be substituted by a radical of the formula -O(CH₃)₂-CH₃.

A represents tetrahydropyranyl, phenyl, pyrimidyl, thienyl or pyridyl, each of which is optionally substituted up to 2 times identically or differently by formyl, carboxyl, straight-chain or branched acyl, alkylthio, alkyloxyacyl, alkoxy or alkoxycarbonyl each having up to 3 carbon atoms, fluorine, chlorine, bromine, nitro, cyano, trifluoromethyl or straight-chain or branched alkyl having up to 3 carbon atoms, which for its part can be substituted by hydroxyl, carboxyl, straight-chain or branched acyl, alkoxy or alkoxycarbonyl each having up to 3 carbon atoms.

and their isomeric forms and salts.

Process for the preparation of compounds of the general formula (I) according to Claim 1, characterized in that, depending on the various meanings of the heterocycles defined under R² and R³, either



15

5

[A] compounds of the general formula (II)

in which

- R1 has the meaning indicated above,
- 5 and
 - D represents radicals of the formula

in which

 R^{18} represents C_1 - C_4 -alkyl,

are converted by reaction with compounds of the general formula (III)

in which

A has the meaning indicated above

in inert solvents, if appropriate in the presence of a base, into the compounds of the general formula (IV) or (IVa)



15

in which

A and R1 have the meaning indicated above,

and, in the case of the compounds of the general formula (IVa), then cyclized with carboxylic acids, nitriles, formamides or guanidinium salts,

and, in the case of the compounds of the general formula (IV), cyclized with 1,3-dicarbonyl derivatives, their salts, tautomers, enol ethers or enamines, in the presence of acids and, if appropriate, under microwaves,

10

or

5

[B] in the case where R² and R³ together form a pyrazine ring, compounds of the general formula (IV) are first converted by nitrosation into the compounds of the general formula (V)

in which

A and R1 have the meaning indicated above,

1000

15

in a second step, by means of a reduction, the compounds of the general

formula (VI)

in which

A and R1 have the meaning indicated above,

are prepared

and finally cyclized with 1,2-dicarbonyl compounds, preferably aqueous glyoxal solution,

or

5

[C] compounds of the general formula (VII)

in which

A1, R2 and R3 have the meaning indicated above,

and

L represents a radical of the formula -SnR¹⁹R²⁰R²¹, ZnR²², iodine, bromine or triflate,

in which



R¹⁹, R²⁰ and R²¹ are identical or different and denote straightchain or branched alkyl having up to 4 carbon atoms,

and

R22 denotes halogen,

5 are reacted with compounds of the general formula (VIII)

R1-T (VIII)

in which

R has the meaning indicated above

and

if $L = SnR^{19}R^{20}R^{21}$ or ZnR^{22}

represents triflate or halogen, preferably bromine,

and

if L = iodine, bromine or triflate,

T represents a radical of the formula $SnR^{19}R^{20}R^{21}$, ZnR^{22} or $BR^{23}R^{24}$.

in which

 R^{19} , R^{20} , R^{21} and R^{22} have the meaning of R^{19} , R^{20} , R^{21} and R^{22} indicated above and are identical to or different from



10

these,

R²⁷ and R²⁴ are identical or different and denote hydroxyl, aryloxy having 6 to 10 carbon atoms or straight-chain or branched alkyl or alkoxy each having up to 5 carbon atoms, or together form a 5- or 6-membered carbocyclic ring,

in a palladium-catalysed reaction in inert solvents, if appropriate in the presence of a base,

[D] if
$$R^1 =$$

10 in which

 R^{23} denotes (C_1-C_0) -alkyl which is optionally substituted by halogen, compounds of the general formula (IX)

in which

A, R² and R³ have the meaning indicated above,



are converted either directly by reaction with the compound of the formula (X)

$$H_2N$$
 R^{25}
 (X)

in which

R25 has the meaning indicated above,

in the system NaOCO-CH3/N-methylpyrrolidine

into the compounds of the general formula (Ia)

in which

R², R³ and A and R²⁵ have the meaning indicated above,

and then, by action of potassium hydroxide in methanol, the acetyl group is removed,

or

first, by reaction of the compounds of the general formula (IX) with the compound of the formula (X), the compounds of the general formula (XI)



10

in which

R2, R3, A and R25 have the meaning indicated above,

are prepared,

and in a further step, by action of potassium hydroxide, the hydroxymethyl compounds are prepared,

and, if appropriate, converted into the corresponding alkoxy compounds by alkylation according to customary methods,

and in the case of the groups $-S(O)_cNR^9R^{10}$ and $-S(O)_cNR^9R^{10}$, starting from the unsubstituted compounds of the general formula (I), first reacted with thionyl chloride and in a second step with the appropriate amines

and, if appropriate, the substituents mentioned under R^1 , R^2 , R^3 and/or A are varied or introduced according to customary methods, preferably by chlorination, catalytic hydrogenation, reduction, oxidation, removal of protective groups and/or nucleophilic substitution.

- Medicaments comprising at least one compound of the general formula (I) according to Claim 1.
 - . Process for the production of medicaments, characterized in that at least one

5

10



compound of the formula (I) according to Claim 1 is converted into a suitable administration form, if appropriate using customary auxiliaries and additives.

- Medicaments comprising at least one compound of the general formula (I) according to Claim 1 in combination with organic nitrates or NO donors.
- Medicaments comprising at least one compound of the general formula (I)
 according to Claim I in combination with compounds which inhibit the
 degradation of cyclic guanosine monophosphate (cGMP).
 - Use of compounds of the general formula (I) according to Claim 1 in the production of medicaments for the treatment of cardiovascular disorders.
- 10 Use of compounds of the general formula (I) according to Claim 1 in the production of medicaments for the treatment of thromboembolic disorders and ischaemias.

